Zimmer Biomet Holdings Inc (NYSE:ZBH)

$ 103.88 0.28 (0.27%) Market Cap: 21.16 Bil Enterprise Value: 26.51 Bil PE Ratio: 21.64 PB Ratio: 1.67 GF Score: 78/100

Q1 2024 Zimmer Biomet Holdings Inc Earnings Call Transcript

May 02, 2024 / 12:30PM GMT

Release Date Price: $118.46 (-0.92%)

Transcript 10-Q8-K

Key Points

Positve

Zimmer Biomet Holdings Inc (ZBH) reported Q1 performance ahead of expectations with 4.4% constant currency revenue growth.
The company reaffirmed its full-year guidance, projecting 5% to 6% constant currency revenue growth and mid- to high single-digit adjusted earnings growth.
Zimmer Biomet Holdings Inc (ZBH) saw strong adoption of ROSA technology and Persona Knee, contributing significantly to the quarter's success.
The company has made significant progress in its strategic priorities, including operational excellence and innovation, with over 40 new products planned for release in the next 24 to 36 months.
Zimmer Biomet Holdings Inc (ZBH) is experiencing healthy end markets driven by demographic shifts and technological advancements, supporting sustained demand.

Negative

Despite positive growth, the company faces challenges with pricing dynamics, although they have improved to about flat compared to historical erosion.
Zimmer Biomet Holdings Inc (ZBH) is still in the process of implementing its restructuring program, which could pose risks if not executed smoothly.
The company's effective tax rate increased by over 200 basis points, which could impact net earnings if it continues to rise.
Zimmer Biomet Holdings Inc (ZBH) reported a reliance on new product introductions for future growth, which could be risky if these products do not perform as expected.
There are ongoing competitive pressures in the orthopedics market, particularly in the robotics and joint replacement segments, which could impact market share and profitability.

Operator

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet First Quarter 2024 Earnings Conference Call. (Operator Instructions). As a reminder, this conference is being recorded today, May 2, 2024. Following today's presentation, there will be a question-and-answer session. (Operator Instructions).

I would now like to turn the conference over to Keri Mattox, Chief Communications and Administration Officer. Please go ahead.

Keri P. Mattox

Zimmer Biomet Holdings, Inc. - SVP and Chief Communications & Administration Officer

Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet's First Quarter 2024 Earnings Conference Call. Joining me today are Ivan Tornos, our President and CEO; and CFO and EVP Finance, Operations and Supply Chain, Suky Upadhyay.

Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.